留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用

郭晖 陈刚

郭晖, 陈刚. Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用[J]. 器官移植, 2021, 12(1): 15-22. doi: 10.3969/j.issn.1674-7445.2021.01.003
引用本文: 郭晖, 陈刚. Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用[J]. 器官移植, 2021, 12(1): 15-22. doi: 10.3969/j.issn.1674-7445.2021.01.003
Guo Hui, Chen Gang. The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 15-22. doi: 10.3969/j.issn.1674-7445.2021.01.003
Citation: Guo Hui, Chen Gang. The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation[J]. ORGAN TRANSPLANTATION, 2021, 12(1): 15-22. doi: 10.3969/j.issn.1674-7445.2021.01.003

Banff移植病理学诊断标准的起源、发展及对器官移植的推动作用

doi: 10.3969/j.issn.1674-7445.2021.01.003
基金项目: 

国家自然科学基金 81771719

中国医学科学院中央级公益性科研院所基本科研业务费专项资金 2019PT320014

详细信息
    作者简介:

    郭晖,研究方向为移植病理学基础与临床应用研究,Email: zcguo@tjh.tjmu.edu.cn

    通讯作者:

    陈刚,研究方向为肾移植及移植免疫,Email: gchen@tjh.tjmu.edu.cn

  • 中图分类号: R617, R36

The origin and development of Banff classification on allograft pathology and its effects in promoting organ transplantation

More Information
  • 摘要: Banff移植病理学会议(Banff会议)的召开及Banff移植病理学诊断标准(Banff标准)的建立是国际移植病理学发展的里程碑。目前世界各器官移植中心均常规依据Banff标准进行移植肾的活组织检查(活检)病理学诊断。随后移植肾Banff标准的研讨和更新模式很快扩展至移植心脏、移植肺、移植肝、移植胰腺和移植小肠等各类移植器官。Banff会议不仅成为包含各类移植器官病理学研讨的专题会议,而且也为各类移植器官的活检逐步制定了统一的诊断标准,更好地促进了器官移植术后并发症的明确诊断和治疗。本文总结了国际移植病理学研究的历史、Banff会议及Banff标准对器官移植的推动作用,旨在为临床器官移植的顺利开展提供参考。

     

  • 表  1  历届Banff会议及其主要进展

    Table  1.   Previous Banff conference and their main progress

    届次 年份 地点 国家 会议内容
    第1届 1991年 Banff 加拿大 建立了Banff会议基本的研讨与运作形式,展开了主要针对移植肾Banff标准的研讨
    第2届 1993年 Banff 加拿大 正式发表1993年移植肾Banff标准(也是Banff标准首次在《Kidney International》杂志上发表)
    第3届 1995年 Banff 加拿大 对1993年移植肾Banff标准进行修订,并整合了CADI以对慢性移植肾病变予以量化评分
    第4届 1997年 Banff 加拿大 借鉴NIH的CCTT标准,公布了1997年移植肾活检的量化诊断标准,使得移植肾Banff标准趋于成型
    第5届 1999年 Banff 加拿大 提出了CAN的概念
    第6届 2001年 Banff 加拿大 关注到AMR、肾间质纤维化及肾小管萎缩病变的意义并展开研讨
    第7届 2003年 Aberdeen 英国 初步提出AMR中肾小管周毛细血管病变的诊断分级;将基因芯片等分子生物学技术应用于Banff标准
    第8届 2005年 Edmonton 加拿大 确立了移植肾AMR,摒弃了CAN;探讨基因芯片等新技术在移植物病理学研究中的应用
    第9届 2007年 La Corũna 西班牙 Banff标准的更新进展、增加了基因组学等组学技术在移植肾排斥反应诊断中的应用研究
    第10届 2009年 Banff 加拿大 针对特殊病变如孤立性血管炎病变、移植肾多瘤病毒肾病等建立了BWG;提出BK病毒相关性肾病诊断方案
    第11届 2011年 Enghien-Les-Bains 法国 进一步完善了AMR诊断标准,认识到慢性微血管病变的意义
    第12届 2013年 Comandatuba-Bahia 巴西 提出了更新的AMR诊断标准,提出C4d阴性AMR的概念
    第13届 2015年 Vancouver 加拿大 借助分子生物学诊断更新了C4d阴性AMR的诊断;提出间质纤维化和肾小管萎缩区域内炎症细胞浸润的意义
    第14届 2017年 Barcelona 西班牙 进一步明确了肾小管萎缩区域内炎症细胞浸润在诊断慢性活动性TCMR中的作用以及分子生物学技术在诊断AMR中的意义
    第15届 2019年 Pittsburgh 美国 进一步确立了慢性活动性TCMR的诊断标准;确立了微血管炎在缺乏C4d阳性和外周血抗体阴性的情况下诊断AMR的意义;探讨了人工智能的深度学习技术在移植病理学中的应用前景
    下载: 导出CSV
  • [1] WILLIAMSON CS. Further studies on the transplantation of the kidney[J]. J Urol, 1926, 16(4):231-254. doi: 10.1016/S0022-5347(17)73405-2
    [2] KREIS H, NOËL LH, LEGENDRE C. The first transplant kidney biopsy ever performed[J]. Am J Transplant, 2013, 13(5):1367-1368. DOI: 10.1111/ajt.12214.
    [3] KISSMEYER-NIELSEN F, OLSEN S, PETERSEN VP, et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells[J]. Lancet, 1966, 2(7465):662-665. DOI: 10.1016/s0140-6736(66)92829-7.
    [4] PORTER KA. Morphological aspects of renal homograft rejection[J]. Br Med Bull, 1965, 21:171-175. DOI: 10.1093/oxfordjournals.bmb.a070388.
    [5] PORTER KA. Rejection in treated renal allografts[J]. J Clin Pathol, 1967, 20:518-534.
    [6] PORTER KA, RENDALL JM, STOLINSKI C, et al. Light and electron microscopic study of biopsies from thirty-three human renal allografts and an isograft 1 3/4-2 1/2 years after transplantation[J]. Ann N Y Acad Sci, 1966, 129(1):615-636. DOI: 10.1111/j.1749-6632.1966.tb12883.x.
    [7] JORDAN SC, MALEKZADEH MH, PENNISI AJ, et al. Accelerated acute rejection of primary renal allografts in pediatric patients[J]. Transplantation, 1980, 30(1):5-8. DOI: 10.1097/00007890-198007000-00002.
    [8] SOULILLOU JP, DE MOUZON-CAMBON A, DUBOIS C, et al. Immunological studies of eluates of 83 rejected kidneys: screening of antibodies directed against T and B lymphocytes, glomerular and tubular basement membranes, DNA, and IgG[J]. Transplantation, 1981, 32(5):368-374. DOI: 10.1097/00007890-198111000-00005.
    [9] HALLORAN PF, WADGYMAR A, RITCHIE S, et al. The significance of the anti-class I antibody response. Ⅰ. clinical and pathologic features of anti-class I-mediated rejection[J]. Transplantation, 1990, 49(1):85-91. DOI: 10.1097/00007890-199001000-00019.
    [10] HALLORAN PF, SCHLAUT J, SOLEZ K, et al. The significance of the anti-class I response. Ⅱ. clinical and pathologic features of renal transplants with anti-class I-like antibody[J]. Transplantation, 1992, 53(3):550-555. doi: 10.1097/00007890-199203000-00011
    [11] FEUCHT HE, FELBER E, GOKEL MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection[J]. Clin Exp Immunol, 1991, 86(3):464-470. DOI: 10.1111/j.1365-2249.1991.tb02954.x.
    [12] FEUCHT HE, SCHNEEBERGER H, HILLEBRAND G, et al. Capillary deposition of C4d complement fragment and early renal graft loss[J]. Kidney Int, 1993, 43(6):1333-1338. DOI: 10.1038/ki.1993.187.
    [13] COLLINS AB, SCHNEEBERGER EE, PASCUAL MA, et al. Complement activation in acute humoral renal allograft rejection: diagnostic significance of C4d deposits in peritubular capillaries[J]. J Am Soc Nephrol, 1999, 10(10):2208-2214. http://europepmc.org/abstract/med/10505698
    [14] BÖHMIG GA, EXNER M, HABICHT A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury[J]. J Am Soc Nephrol, 2002, 13(4):1091-1099. http://www.ncbi.nlm.nih.gov/pubmed/11912271
    [15] BÖHMIG GA, REGELE H, EXNER M, et al. C4d-positive acute humoral renal allograft rejection: effective treatment by immunoadsorption[J]. J Am Soc Nephrol, 2001, 12(11):2482-2489. http://www.ncbi.nlm.nih.gov/pubmed/11675426
    [16] THIRU S, MAHER ER, HAMILTON DV, et al. Tubular changes in renal transplant recipients on cyclosporine[J]. Transplant Proc, 1983, 15:2846-2851. http://www.researchgate.net/publication/290811197_tubular_changes_in_renal_transplant_recipients_on_cyclosporine
    [17] CALNE RY, WHITE DJ, THIRU S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors[J]. Lancet, 1978, 2(8104/8105):1323-1327. DOI: 10.1016/s0140-6736(78)91970-0.
    [18] MIHATSCH MJ, THIEL G, SPICHTIN HP. Morphological findings in kidney transplants after treatment with cyclosporin[J]. Transplant Proc, 1983, 15(4):2821-2835. http://www.researchgate.net/publication/279690992_Morphological_findings_in_kidney_transplants_after_treatment_with_cyclosporin
    [19] MIHATSCH MJ, HELMCHEN U, CASANOVA P, et al. Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus[J]. Klin Wochenschr, 1991, 69(8):354-359. DOI: 10.1007/BF02115783.
    [20] NEILD GH, REUBEN R, HARTLEY RB, et al. Glomerular thrombi in renal allografts associated with cyclosporin treatment[J]. J Clin Pathol, 1985, 38(3):253-258. DOI: 10.1136/jcp.38.3.253.
    [21] NIZZE H, MIHATSCH MJ, ZOLLINGER HU, et al. Cyclosporine-associated nephropathy in patients with heart and bone marrow transplants[J]. Clin Nephrol, 1988, 30(5):248-260. http://europepmc.org/abstract/MED/3063420
    [22] RANDHAWA PS, SHAPIRO R, JORDAN ML, et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. clinical significance and comparison with cyclosporine[J]. Am J Surg Pathol, 1993, 17(1):60-68. DOI: 10.1097/00000478-199301000-00007.
    [23] DEMETRIS AJ, JAFFE R, TZAKIS A, et al. Antibody mediated rejection of human liver allografts: transplantation across ABO blood group barriers[J]. Transplant Proc, 1989, 21(1 Pt 2):2217-2220.
    [24] DEMETRIS AJ, MURASE N, NAKAMURA K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection[J]. Semin Liver Dis, 1992, 12(1):51-59. DOI: 10.1055/s-2007-1007376.
    [25] SNOVER DC, FREESE DK, SHARP HL, et al. Liver allograft rejection. an analysis of the use of biopsy in determining outcome of rejection[J]. Am J Surg Pathol, 1987, 11(1):1-10. DOI: 10.1097/00000478-198701000-00001.
    [26] HÜBSCHER S. Diagnosis and grading of liver allograft rejection: a European perspective[J]. Transplant Proc, 1996, 28(1):504-507. http://europepmc.org/abstract/MED/8644330
    [27] Terminology of chronic hepatitis, hepatic allograft rejection, and nodular lesions of the liver: summary of recommendations developed by an international working party, supported by the World Congresses of Gastroenterology, Los Angeles, 1994[J]. Am J Gastroenterol, 1994, 89(8 Suppl): S177-S181.
    [28] LUDWIG J, WIESNER RH, BATTS KP, et al. The acute vanishing bile duct syndrome (acute irreversible rejection) after orthotopic liver transplantation[J]. Hepatology, 1987, 7(3):476-483. DOI: 10.1002/hep.1840070311.
    [29] WILLIAMS JW, PETERS TG, VERA SR, et al. Biopsy-directed immunosuppression following hepatic transplantation in man[J]. Transplantation, 1985, 39(6): 589-596. DOI: 10.1097/00007890-198506000-00003.
    [30] DEMETRIS AJ, QIAN SG, SUN H, et al. Liver allograft rejection: an overview of morphologic findings[J]. Am J Surg Pathol, 1990, 14 (Suppl 1):49-63. http://europepmc.org/abstract/MED/2183642
    [31] GORDON RD, IWATSUKI S, ESQUIVEL CO, et al. Liver transplantation across ABO blood groups[J]. Surgery, 1986, 100(2):342-348. http://europepmc.org/abstract/MED/3526607
    [32] CAVES PK, STINSON EB, BILLINGHAM M, et al. Percutaneous transvenous endomyocardial biopsy in human heart recipients. experience with a new technique[J]. Ann Thorac Surg, 1973, 16(4):325-336. DOI: 10.1016/s0003-4975(10)65002-3.
    [33] BILLINGHAM ME. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy[J]. J Heart Transplant, 1990, 9(3 Pt 2):272-276.
    [34] HAMMOND EH, YOWELL RL, NUNODA S, et al. Vascular (humoral) rejection in heart transplantation: pathologic observations and clinical implications[J].J Heart Transplant, 1989, 8(6):430-443.
    [35] JOSHI A, MASEK MA, BROWN BW JR, et al. "Quilty" revisited: a 10-year perspective[J]. Hum Pathol, 1995, 26(5):547-557. DOI: 10.1016/0046-8177(95)90252-x.
    [36] URETSKY BF, MURALI S, REDDY PS, et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone[J]. Circulation, 1987, 76(4):827-834. DOI: 10.1161/01.cir.76.4.827.
    [37] NARROD J, KORMOS R, ARMITAGE J, et al. Acute rejection and coronary artery disease in long-term survivors of heart transplantation[J]. J Heart Transplant, 1989, 8(5):418-420. http://europepmc.org/abstract/MED/2795285
    [38] ZERBE T, URETSKY B, KORMOS R, et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen[J]. J Heart Lung Transplant, 1992, 11(3 Pt 2):S104-S110. http://www.ncbi.nlm.nih.gov/pubmed/1622988
    [39] MCDONALD K, RECTOR TS, BRAULIN EA, et al. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection[J]. Am J Cardiol, 1989, 64(5):359-362. DOI: 10.1016/0002-9149(89)90535-3.
    [40] CASTANEDA AR, ARNAR O, SCHMIDT-HABELMAN P, et al. Cardiopulmonary autotransplantation in primates[J]. J Cardiovasc Surg (Torino), 1972, 13(5):523-531. http://www.ncbi.nlm.nih.gov/pubmed/4628834
    [41] STEWART S, CIULLI F, WELLS FC, et al. Pathology of unused donor lungs[J]. Transplant Proc, 1993, 25(1 Pt 2):1167-1168. http://www.ncbi.nlm.nih.gov/pubmed/8442074
    [42] STEWART S, HIGENBOTTAM TW, HUTTER JA, et al. Histopathology of transbronchial biopsies in heart-lung transplantation[J]. Transplant Proc, 1988, 20:764-766. http://www.researchgate.net/publication/316495137_Histopathology_of_transbronchial_biopsies_in_heart-lung_transplantation
    [43] BURKE CM, THEODORE J, DAWKINS KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation[J]. Chest, 1984, 86(6):824-829. DOI: 10.1378/chest.86.6.824.
    [44] SIBLEY RK, SUTHERLAND DER. Pancreas transplantation. an immunohistologic and histopathologic examination of 100 grafts[J]. Am J Pathol, 1987, 128(1):151-170. http://europepmc.org/articles/PMC1899795/
    [45] NAKHLEH RE, GRUESSNER RW, SWANSON PE, et al. Pancreas transplant pathology. a morphologic, immunohistochemical, and electron microscopic comparison of allogeneic grafts with rejection, syngeneic grafts, and chronic pancreatitis[J]. Am J Surg Pathol, 1991, 15(3):246-256. doi: 10.1097/00000478-199103000-00005
    [46] NAKAMURA K, NALESNIK M, JAFFE R, et al. Morphological monitoring of human small bowel allografts[J]. Transplant Proc, 1993, 25(1 Pt 2):1212. http://europepmc.org/articles/PMC2963862
    [47] ROSEMURGY AS, SCHRAUT WH. Small bowel allografts. sequence of histologic changes in acute and chronic rejection[J]. Am J Surg, 1986, 151(4):470-475. DOI: 10.1016/0002-9610(86)90106-6.
    [48] SOLEZ K, RACUSEN LC. The Banff classification revisited[J]. Kidney Int, 2013, 83(2):201-206. DOI: 10.1038/ki.2012.395.
    [49] Banff Foundation for Allograft Pathology[EB/OL]. [2020-11-01]. https://www.banfffoundation.org.
    [50] The Banff Conferences on Allograft Pathology[EB/OL]. [2020-11-01]. https://cybernephrology.ualberta.ca/Banff/.
    [51] SOLEZ K, AXELSEN RA, BENEDIKTSSON H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology[J]. Kidney Int, 1993, 44(2):411-422. DOI: 10.1038/ki.1993.259.
    [52] RACUSEN LC, SOLEZ K, COLVIN RB, et al. The Banff 97 working classification of renal allograft pathology[J]. Kidney Int, 1999, 55(2):713-723. DOI: 10.1046/j.1523-1755.1999.00299.x.
    [53] RACUSEN LC, COLVIN RB, SOLEZ K, et al. Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection[J]. Am J Transplant, 2003, 3(6):708-714. DOI: 10.1034/j.1600-6143.2003.00072.x.
    [54] SOLEZ K, COLVIN RB, RACUSEN LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN') [J]. Am J Transplant, 2007, 7(3):518-526. DOI: 10.1111/j.1600-6143.2006.01688.x.
    [55] SOLEZ K, COLVIN RB, RACUSEN LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions[J]. Am J Transplant, 2008, 8(4):753-760. DOI: 10.1111/j.1600-6143.2008.02159.x.
    [56] SIS B, MENGEL M, HAAS M, et al. Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups[J]. Am J Transplant, 2010, 10(3):464-471. DOI: 10.1111/j.1600-6143.2009.02987.x.
    [57] MENGEL M, SIS B, HAAS M, et al. Banff 2011 meeting report: new concepts in antibody-mediated rejection[J]. Am J Transplant, 2012, 12(3):563-570. DOI: 10.1111/j.1600-6143.2011.03926.x.
    [58] HAAS M, SIS B, RACUSEN LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions[J]. Am J Transplant, 2014, 14(2):272-283. DOI: 10.1111/ajt.12590.
    [59] LOUPY A, HAAS M, ROUFOSSE C, et al. The Banff 2019 kidney meeting report (Ⅰ): updates on and clarification of criteria for T cell- and antibody-mediated rejection[J]. Am J Transplant, 2020, 20(9):2318-2331. DOI: 10.1111/ajt.15898.
    [60] 黄亚冰, 郭晖, 钟伟雄.2017年Banff移植病理学会议纪要及移植肾病理诊断分类修订[J].中华器官移植杂志, 2018, 39(9):565-570. DOI: 10.3760/cma.j.issn. 0254-1785.2018.09.011.

    HUANG YB, GUO H, ZHONG WX. 2017 Banff transplant pathology meeting summary and revised classification of transplant kidney pathology [J]. Chin J Organ Transplant, 2018, 39(9): 565-570. DOI: 10.3760/cma.j.issn.0254-1785.2018.09.011.
  • 加载中
表(1)
计量
  • 文章访问数:  306
  • HTML全文浏览量:  554
  • PDF下载量:  117
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-11-10
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2021-01-19

目录

    /

    返回文章
    返回